Anti-interferon-α antibodies
AssigneeGenentech, Inc.
InventorsAnan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
Claims39
An anti-IFN-α monoclonal antibody which binds to and neutralizes a biological activity of at least IFN-α subtypes, IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.
An antibody, or antigen binding fragment thereof, comprising a heavy chain variable domain and a light chain variable domain, wherein the light chain variable domain comprises the following CDR's:
- (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO:
- 7);
- (b) L2 of the formula YASNLES (SEQ ID NO:
- 8);
- and
- (c) L3 of the formula QHSWGIPRTF (SEQ ID NO:
- 9);
- and wherein the antibody or antigen binding fragment specifically binds to at least IFN-α subtypes IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.
An antibody, or antigen binding fragment thereof, comprising a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises the following CDR's:
- (a) H1 of the formula GYTFTEYIIH (SEQ ID NO;
- 10);
- (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO:
- 11);
- and
- (c) H3 of the formula WISDFFDY (SEQ ID NO:
- 12);
- and wherein the antibody or antigen binding fragment specifically binds to at least IFN-α subtypes IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.
An anti-IFN-α antibody comprising
- (A) at least one light chain or an antigen binding fragment thereof, comprising the following CDR's:
- (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO:
- 7);
- (b) L2 of the formula YASNLES (SEQ ID NO:
- 8);
- and
- (c) 3 of the formula QHSWGIPRTF (SEQ ED NO:
- 9);
- and
- (B) at least one heavy chain or an antigen binding fragment thereof, comprising the following CDR's:
- (a) H1 of the formula GYTFTEYIIH (SEQ D NO:
- 10);
- (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO:
- 11);
- and
- (c) H3 of the formula WISDFFDY (SEQ ID NO:
- 12).
A hybridoma cell line deposited with ATCC on Jan. 18, 2001 and having accession No. PTA-2917.
Dependencies are inferred from the claim text.